Physician profile
Mark J Tramo
NPI 1447232731
$30,998.05
in general payments reported to CMS, 2019-2025
30 companies · $8,488 in 2025
The $8,488 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $709 · 2021: $1,123 · 2022: $914 · 2023: $10K · 2024: $8,358 · 2025: $8,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $5,599 · Travel and Lodging: $72.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,656.25 |
| Food and Beverage | $5,598.86 |
| Travel and Lodging | $72.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,889.67 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $1,103.70 | 2023-2025 | |
| Biogen, INC. | $588.92 | 2019-2025 | Vumerity |
| Amgen INC. | $456.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $400.34 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $383.58 | 2019-2025 | Austedo Xr, Austedo Xr |
| Adamas Pharmaceuticals, INC. | $356.43 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $352.58 | 2019-2025 | Nuplazid |
| Emd Serono, INC. | $241.48 | 2019-2023 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $230.91 | 2021-2025 | Ultomiris |
| Abbott Laboratories | $212.54 | 2019-2025 | Infinity |
| Biohaven Pharmaceutical Holding Company Ltd. | $210.09 | 2022 | |
| Amneal Pharmaceuticals LLC | $209.35 | 2022-2025 | Crexont, Rytary |
| Axsome Therapeutics, INC. | $208.36 | 2025 | Symbravo |
| Eisai INC. | $166.16 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $154.77 | 2021 | |
| Lilly USA, LLC | $129.56 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $119.70 | 2024-2025 | Rexulti |
| Genzyme Corporation | $104.94 | 2020-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $84.00 | 2025 | Lumryz |
| Alnylam Pharmaceuticals INC. | $74.16 | 2023-2025 | Amvuttra, Onpattro |
| Mdd US Operations, LLC | $72.56 | 2020-2023 | Apokyn |
| Allergan, INC. | $65.93 | 2020 | |
| Bausch Health US, LLC | $47.03 | 2020 | |
| Supernus Pharmaceuticals, INC. | $42.88 | 2025 | Qelbree |
| Genentech USA, INC. | $33.52 | 2025 | Ocrevus Zunovo |
| Zyla Life Sciences, INC. | $17.81 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.97 | 2023 | Ztlido |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Ucb, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tramo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.